Drug therapy has transformed the management of numerous diseases. However, patients receiving the same medication at the same dose can experience substantially different outcomes.

Some patients obtain the expected therapeutic benefit, whereas others show inadequate responses.

In some cases, patients experience adverse drug reactions despite receiving standard doses.

These differences may result from age, body weight, organ function, diet, drug interactions, disease status, adherence, and genetic variation.

Pharmacogenomics focuses on the genetic component of variability in drug response.

The field examines how inherited differences in DNA influence drug absorption, distribution, metabolism, elimination, pharmacodynamic effects, and toxicity.

The increasing availability of genomic technologies has made it possible to identify clinically relevant variants and incorporate genetic information into treatment decisions.

Personalized drug therapy aims to move beyond a one-size-fits-all approach by considering patient-specific biological characteristics.

Pharmacogenomics represents an important component of this approach.

Molecular Basis of Pharmacogenomics

Genetic variants can affect drug response through several mechanisms.

Variants in genes encoding drug-metabolizing enzymes may alter the rate at which medications are converted into active or inactive metabolites.

Variants in transporters can affect movement of drugs into or out of cells.

Genetic differences in drug targets can alter pharmacodynamic sensitivity.

Immune-related genetic variants can increase susceptibility to severe adverse drug reactions.

The consequences of these variants depend on the specific drug and its pharmacological pathway.

Major Pharmacogenomic Genes

Several genes have demonstrated clinically important associations with drug response.

CYP2D6 and Drug Metabolism

CYP2D6 is one of the most extensively studied pharmacogenomic enzymes.

Genetic variation produces different metabolic phenotypes.

Individuals may be categorized broadly as poor, intermediate, normal, or ultrarapid metabolizers.

These differences can influence drug exposure.

For drugs requiring CYP2D6-mediated activation, reduced enzyme activity may lead to reduced therapeutic effects.

For drugs inactivated by CYP2D6, reduced metabolism may increase drug exposure and adverse effects.

CYP2D6 therefore illustrates the importance of considering both the metabolic pathway and the pharmacological properties of the drug.

CYP2C19 and Antiplatelet Therapy

CYP2C19 is particularly important in the metabolism and activation of several medications.

Clopidogrel is a prodrug that requires metabolic activation.

Individuals carrying reduced-function CYP2C19 alleles may have lower production of the active metabolite and reduced platelet inhibition.

This can contribute to differences in therapeutic effectiveness.

Genotype-guided selection of antiplatelet therapy has therefore become an important example of pharmacogenomic application.

CYP2C9 and VKORC1 in Warfarin Therapy

Warfarin has a narrow therapeutic window.

Both CYP2C9 and VKORC1 contribute to variability in warfarin response.

CYP2C9 affects metabolism of the active S-enantiomer of warfarin.

VKORC1 encodes vitamin K epoxide reductase complex subunit 1, the pharmacological target of warfarin.

Genetic variation in these genes can influence the dose required to achieve therapeutic anticoagulation.

Other factors—including age, diet, interacting medications, and clinical conditions—also influence dosing.

Therefore, genetic information is most useful when incorporated into a broader clinical dosing strategy.

TPMT and NUDT15 in Thiopurine Therapy

Thiopurine medications are used in several hematological, oncological, inflammatory, and autoimmune conditions.

TPMT and NUDT15 participate in thiopurine metabolism.

Reduced activity associated with certain genetic variants can increase exposure to active thiopurine metabolites.

This may increase the risk of severe bone marrow suppression.

Pre-treatment pharmacogenomic testing can help identify patients who may require substantial dose reduction or alternative treatment.

This represents an important example of pharmacogenomics being used to prevent serious drug toxicity.

DPYD and Fluoropyrimidine Toxicity

Fluoropyrimidines are widely used anticancer drugs.

DPYD encodes dihydropyrimidine dehydrogenase, an enzyme involved in fluoropyrimidine metabolism.

Reduced DPYD activity can increase exposure to active drug metabolites.

Patients carrying clinically important reduced-function variants may have increased risk of severe or potentially life-threatening toxicity.

Genetic assessment can therefore help identify patients who may require alternative dosing strategies or treatment options.

HLA-Associated Drug Reactions

Certain human leukocyte antigen variants are strongly associated with severe immune-mediated drug reactions.

These associations are clinically important because the reactions can be severe and difficult to predict using conventional clinical characteristics alone.

Examples include associations between particular HLA variants and hypersensitivity reactions to specific medications.

Pharmacogenomic testing can be particularly valuable when a strong and reproducible association exists between a genetic variant and a serious adverse reaction.

Pharmacogenomics in Oncology

Cancer treatment represents one of the most important areas of precision medicine.

Tumors contain genetic alterations that can influence therapeutic sensitivity.

Pharmacogenomics can operate at two levels.

The first involves inherited genetic variation affecting the patient's response or toxicity.

The second involves molecular characteristics of tumor cells that identify therapeutic targets.

Genomic information can therefore help select therapies that are more likely to be effective for particular tumor profiles.

Targeted therapies directed against specific molecular alterations have transformed treatment for several cancers.

Pharmacogenomics and Cardiovascular Medicine

Cardiovascular medicine provides several important examples of pharmacogenomic application.

Warfarin dosing can be influenced by CYP2C9 and VKORC1 variation.

CYP2C19 genotype can influence response to clopidogrel.

SLCO1B1 variants have been investigated in relation to statin-associated muscle toxicity.

These examples demonstrate how genetic information can potentially improve both drug selection and dosing.

Pharmacogenomics in Psychiatry

Psychiatric drug response is highly variable.

Antidepressants and other psychotropic medications are metabolized by several cytochrome P450 enzymes.

Genetic variation in CYP2D6 and CYP2C19 can influence drug exposure for selected medications.

Pharmacogenomic information may therefore assist in identifying patients who are likely to have unusual metabolism.

However, treatment response in psychiatric disorders is influenced by many biological and psychosocial factors, meaning genetic information should be interpreted as one component of clinical decision-making.

Figure 1. Pharmacogenomics in Personalized Drug Therapy

                    PATIENT

                       │

        ┌──────────────┼──────────────┐

        ▼              ▼              ▼

     GENOME        CLINICAL DATA   ENVIRONMENT

        │              │              │

        ▼              ▼              ▼

 Genetic Variants   Age, Disease   Diet, Drugs,

        │           Organ Function  Lifestyle

        └──────────────┼──────────────┘

                       ▼

              Drug Response Profile

                       │

          ┌────────────┼────────────┐

          ▼            ▼            ▼

       Efficacy      Toxicity    Metabolism

          │            │            │

          └────────────┼────────────┘

                       ▼

             Personalized Therapy

                       │

                       ▼

              Improved Treatment

                  and Safety

Figure 1: Conceptual framework illustrating how genetic information can be integrated with clinical and environmental factors to guide individualized drug selection and dosing.

Pharmacogenomic Testing

Pharmacogenomic testing can be performed using several molecular approaches.

Genotyping assays can identify specific variants associated with drug response.

Targeted panels can analyze multiple pharmacogenes simultaneously.

More comprehensive sequencing approaches can identify a broader range of genetic variants.

The clinical value of testing depends on the quality of evidence supporting each gene–drug relationship.

Not every detected variant has a known clinical significance.

Therefore, laboratory interpretation and validated clinical guidelines are essential.

Review Design

The present article was prepared as a narrative review examining the role of pharmacogenomics in personalized drug therapy.

Literature Search

Relevant scientific literature was considered from major biomedical databases and peer-reviewed journals.

Search terms included combinations of “pharmacogenomics,” “pharmacogenetics,” “personalized drug therapy,” “drug response,” “adverse drug reactions,” “CYP2D6,” “CYP2C19,” “CYP2C9,” “VKORC1,” “TPMT,” “NUDT15,” “DPYD,” and “HLA pharmacogenomics.”

Inclusion Criteria

Studies addressing clinically relevant genetic variants, drug metabolism, therapeutic response, adverse drug reactions, pharmacogenomic testing, and personalized treatment were considered relevant.

Data Synthesis

The literature was organized according to drug metabolism, pharmacodynamic pathways, adverse drug reactions, therapeutic areas, clinical implementation, and future applications.

Results

The reviewed evidence indicates that inherited genetic variation can contribute significantly to differences in drug response.

CYP2D6 and CYP2C19 variation can influence the metabolism of several commonly prescribed medications.

CYP2C9 and VKORC1 variation contributes to variability in warfarin dose requirements.

TPMT and NUDT15 variants can identify patients at increased risk of thiopurine toxicity.

DPYD variants can identify individuals with increased risk of severe fluoropyrimidine toxicity.

Specific HLA variants can identify patients at increased risk of serious immune-mediated adverse drug reactions.

These findings demonstrate that pharmacogenomic testing can have particular value when a strong gene–drug association exists and when the clinical consequences of inappropriate therapy are substantial.

Pharmacogenomics has changed the concept of individualized drug therapy by providing a molecular explanation for some of the variability observed between patients.

Traditional prescribing approaches generally begin with standard doses derived from population-level clinical trials.

Although this approach is effective for many patients, a subset may receive insufficient drug exposure or excessive exposure.

Genetic variation can explain part of this variability.

Drug-metabolizing enzymes are particularly important.

CYP2D6 and CYP2C19 demonstrate how differences in metabolic activity can alter circulating drug concentrations.

The clinical effect depends on whether metabolism activates or inactivates the medication.

Pharmacogenomics is particularly valuable when the consequences of abnormal metabolism are clinically significant.

Thiopurine therapy provides a strong example.

Testing TPMT and NUDT15 can identify patients with increased susceptibility to severe toxicity.

Similarly, DPYD testing can help identify patients who may be at increased risk of fluoropyrimidine-associated toxicity.

Another important area is immune-mediated drug reactions.

Certain HLA variants can markedly increase the risk of severe adverse reactions.

Because these reactions can be serious, genetic screening can be particularly valuable when a strong association has been established.

However, pharmacogenomics should not be considered a replacement for clinical judgment.

Genetic variation represents only one component of drug response.

Age, kidney and liver function, interacting medications, disease severity, diet, adherence, and other factors can substantially influence treatment outcomes.

A major challenge is also population diversity.

Many pharmacogenomic studies have historically included participants from populations of European ancestry.

Allele frequencies can differ substantially among populations.

Consequently, pharmacogenomic implementation requires evidence from diverse populations to ensure equitable clinical benefit.

Advantages of Pharmacogenomic-Guided Therapy

Limitations and Challenges

Despite substantial progress, several limitations remain.

Not all pharmacogenomic associations have strong clinical evidence.

Some variants produce relatively small effects.

Genetic testing may also be unavailable or costly in some healthcare systems.

Interpretation can be challenging when patients carry rare or previously uncharacterized variants.

Electronic health records must be capable of storing genetic results and presenting clinically relevant recommendations at the appropriate time.

Another challenge involves genetic diversity.

A pharmacogenomic test developed primarily using one population may not perform equally well across all populations.

These issues must be addressed to ensure that personalized therapy is both clinically useful and equitable.

Clinical Implementation

Successful implementation requires coordination between laboratories, physicians, pharmacists, genetic specialists, and healthcare information systems.

Pharmacogenomic results should ideally remain available throughout a patient's medical history because genetic information generally does not change.

Clinical decision-support systems can alert healthcare professionals when a patient's genotype is relevant to a prescribed medication.

Clear reporting is also important.

Results should be translated into clinically meaningful phenotypes or recommendations rather than presented only as genetic variants.

Future Perspectives

The future of pharmacogenomics will likely involve integration with broader precision-medicine approaches.

Whole-genome and exome sequencing may identify multiple variants relevant to treatment.

Artificial intelligence and computational models may help integrate genomic data with clinical variables.

Multi-gene pharmacogenomic panels may become increasingly common.

Another important development will be expansion of pharmacogenomic evidence across diverse populations.

Pharmacogenomics may also become increasingly integrated into electronic prescribing systems.

Rather than ordering genetic testing only after treatment failure, pre-emptive testing could provide relevant information before medications are prescribed.

This approach may be particularly useful for patients who are likely to receive multiple medications throughout their lifetime.

Pharmacogenomics provides a molecular framework for understanding differences in medication response among individuals.

Genetic variants affecting drug-metabolizing enzymes, transporters, therapeutic targets, and immune pathways can influence drug efficacy and toxicity.

Clinically important examples include CYP2D6, CYP2C19, CYP2C9, VKORC1, TPMT, NUDT15, DPYD, and HLA-associated drug responses.

The integration of pharmacogenomic information with clinical characteristics can improve medication selection and dosing in appropriate situations.

Nevertheless, genetic information should be interpreted alongside age, disease status, organ function, drug interactions, and other clinical factors.

Future advances in genomic sequencing, diverse population research, electronic clinical decision support, and precision medicine are likely to expand the role of pharmacogenomics.

Ultimately, pharmacogenomic-guided therapy may help move healthcare toward safer, more effective, and increasingly individualized medication management.

1. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487–491.
2. Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nature Reviews Genetics. 2023;24:350–362.
3. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526:343–350.
4. Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics. Lancet. 2019;394:521–532.
5. Johnson JA, Evans WE. Molecular diagnostics as a predictive tool in pharmacotherapy. Clinical Pharmacology & Therapeutics. 2013;93:178–180.
6. Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy. Clinical Pharmacology & Therapeutics. 2013;94:317–323.
7. Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium. Genetics in Medicine. 2017;19:215–223.
8. Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes. Clinical Pharmacology & Therapeutics. 2019;105:1095–1105.
9. Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium guideline for DPYD genotype and fluoropyrimidine dosing. Clinical Pharmacology & Therapeutics. 2018;103:210–216.
10. Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium guideline for pharmacogenetics-guided warfarin dosing. Clinical Pharmacology & Therapeutics. 2017;102:397–404.
11. Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C19 genotype and clopidogrel therapy. Clinical Pharmacology & Therapeutics. 2022;112:959–967.
12. Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clinical Pharmacology & Therapeutics. 2013;93:402–408.
13. Klein TE, Altman RB, Eriksson N, et al. Estimation of clinical implications of CYP2D6 genotype in drug response. Nature Reviews Drug Discovery. 2012;11:547–559.
14. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB pathway. Clinical Pharmacology & Therapeutics. 2011;89:601–606.
15. Daly AK. Pharmacogenetics and human genetic diversity. Current Opinion in Pharmacology. 2017;37:93–97.
16. Lauschke VM, Ingelman-Sundberg M. Precision medicine and rare genetic variants. Trends in Pharmacological Sciences. 2016;37:85–86.
17. Suwinski P, Starlinger J, Sasane S, et al. Applying precision medicine in clinical practice: a systematic review of barriers and enablers. Nature Reviews Drug Discovery. 2019;18:489–501.
18. Mizzi C, Peters B, Mitropoulou C, et al. Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics. 2014;15:1569–1581.
19. van der Wouden CH, Cambon-Thomsen A, Cecchin E, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the Ubiquitous Pharmacogenomics Consortium. Clinical Pharmacology & Therapeutics. 2017;101:341–358.
20. Dunnenberger HM, Crews KR, Hoffman JM, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annual Review of Pharmacology and Toxicology. 2015;55:89–106.